Aclarion Future Growth

Future criteria checks 0/6

Aclarion's earnings are forecast to decline at 2.4% per annum. EPS is expected to grow by 118.8% per annum.

Key information

-2.4%

Earnings growth rate

118.8%

EPS growth rate

Healthcare Services earnings growth	27.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	05 Mar 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:ACON - Analysts future estimates and past financials data (USD Millions)
Date	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	-6	N/A	N/A	1
12/31/2023	-5	-4	-4	N/A
9/30/2023	-5	-4	-4	N/A
6/30/2023	-5	-4	-4	N/A
3/31/2023	-7	-6	-6	N/A
12/31/2022	-7	-5	-5	N/A
9/30/2022	-8	-5	-5	N/A
6/30/2022	-9	-5	-4	N/A
3/31/2022	-6	-3	-2	N/A
12/31/2021	-6	-3	-2	N/A
9/30/2021	-5	-2	-2	N/A
6/30/2021	-5	-4	-3	N/A
3/31/2021	-5	-4	-3	N/A
12/31/2020	-5	-4	-4	N/A
12/31/2019	-5	-4	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACON is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACON is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACON is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ACON's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ACON's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ACON's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Aclarion Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Aclarion Receives Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Aclarion, Inc. has completed a Composite Units Offering in the amount of $3.0015 million.

Full year 2023 earnings released: US$8.82 loss per share (vs US$19.61 loss in FY 2022)

Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution

New major risk - Shareholder dilution

Aclarion, Inc. announced that it has received $0.25 million in funding

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.21 loss in 3Q 2022)

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Nasdaq Staff Determines to Delist the Aclarion Common Stock from Nasdaq, Unless the Company Timely Requests an Appeal of the Staff’s Determination to A Hearings Panel

Nasdaq Confirms Aclarion Regains Compliance with Rule 5250(c)(1) Regarding Filing of 10-Q Report

Aclarion Announces Update on Non-Compliance Notice from Nasdaq Regarding Late Filing of 10-Q Report

High number of new and inexperienced directors

Aclarion Receives Non-Compliance Notice From Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aclarion, Inc. Receives Nasdaq Notice Regarding Late Filing of 10-Q Report

Aclarion, Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.25 loss per share (vs US$6.58 loss in FY 2021)

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc. Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Aclarion, Inc.'s Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings released: US$1.35 loss per share (vs US$0.81 loss in 1Q 2021)

Director recently bought US$150k worth of stock

High number of new directors

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies